HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mutations in human CPO gene predict clinical expression of either hepatic hereditary coproporphyria or erythropoietic harderoporphyria.

Abstract
Hereditary coproporphyria (HCP), an autosomal dominant acute hepatic porphyria, results from mutations in the gene that encodes coproporphyrinogen III oxidase (CPO). HCP (heterozygous or rarely homozygous) patients present with an acute neurovisceral crisis, sometimes associated with skin lesions. Four patients (two families) have been reported with a clinically distinct variant form of HCP. In such patients, the presence of a specific mutation (K404E) on both alleles or associated with a null allele, produces a unifying syndrome in which hematological disorders predominate: 'harderoporphyria'. Here, we report the fifth case (from a third family) with harderoporphyria. In addition, we show that harderoporphyric patients exhibit iron overload secondary to dyserythropoiesis. To investigate the molecular basis of this peculiar phenotype, we first studied the secondary structure of the human CPO by a predictive method, the hydrophobic cluster analysis (HCA) which allowed us to focus on a region of the enzyme. We then expressed mutant enzymes for each amino acid of the region of interest, as well as all missense mutations reported so far in HCP patients and evaluated the amount of harderoporphyrin in each mutant. Our results strongly suggest that only a few missense mutations, restricted to five amino acids encoded by exon 6, may accumulate significant amounts of harderoporphyrin: D400-K404. Moreover, all other type of mutations or missense mutations mapped elsewhere throughout the CPO gene, lead to coproporphyrin accumulation and subsequently typical HCP. Our findings, reinforced by recent crystallographic results of yeast CPO, shed new light on the genetic predisposition to HCP. It represents a first monogenic metabolic disorder where clinical expression of overt disease is dependent upon the location and type of mutation, resulting either in acute hepatic or in erythropoietic porphyria.
AuthorsCaroline Schmitt, Laurent Gouya, Eva Malonova, Jérôme Lamoril, Jean-Michel Camadro, Magali Flamme, Christian Rose, Said Lyoumi, Vasco Da Silva, Catherine Boileau, Bernard Grandchamp, Carole Beaumont, Jean-Charles Deybach, Hervé Puy
JournalHuman molecular genetics (Hum Mol Genet) Vol. 14 Issue 20 Pg. 3089-98 (Oct 15 2005) ISSN: 0964-6906 [Print] England
PMID16159891 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Heme
  • Coproporphyrinogen Oxidase
Topics
  • Amino Acid Sequence
  • Coproporphyria, Hereditary (enzymology, genetics, pathology)
  • Coproporphyrinogen Oxidase (chemistry, genetics, metabolism)
  • Exons (genetics)
  • Gene Expression
  • Heme (biosynthesis)
  • Humans
  • Iron Overload (metabolism)
  • Molecular Sequence Data
  • Mutation (genetics)
  • Mutation, Missense (genetics)
  • Pedigree
  • Porphyrias, Hepatic (enzymology, genetics, pathology)
  • Protein Structure, Secondary
  • Sequence Homology

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: